HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data

Atherosclerosis

Volumn 138, Issue 1, 1998, Pages 11-24

  Crouse III, John R ^a   Byington, Robert P ^a   Furberg, Curt D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Coronary heart disease; HMG CoA reductase inhibitors; Primary prevention; Secondary prevention; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE;

EID: 0032076753     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00014-8     Document Type: Article

References (100)

1. Becker DM. Clinical approaches to cardiovascular disease: smoking. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. American Heart Association, 1994:143-59.
2. Orchard TJ. Diabetes. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. American Heart Association, 1994:159-73.
3. Wolf PA. Epidemiology of stroke. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. American Heart Association 1994:67-83.
4. Gotto AM. Lipid and lipoprotein disorders. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. American Heart Association 1994:107-31.
5. Criqui MH. Peripheral arterial disease. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M, editors. Primer in Preventive Cardiology. American Heart Association 1994:83-93.
6. Holme I, Enger SC, Helgeland A, Hjermann I, Leren P, Lund-Larsen PG, Solberg LA, Strong JP Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries. Arteriosclerosis. 1:1981;250-2566.
7. Young W, Gofman JW, Tandy R, Malamud N, Waters ESG The quantitation of atherosclerosis, III: the extent of correlation of degrees of atherosclerosis within and between the coronary and cerebral vacular beds. Am J Cardiol. 6:1960;300-308.
8. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson C, Heiss G, Crouse JR Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case control study. Circulation. 82:1990;1230-1242.
9. Tanake H, Nishino M, Ishida M, Fukunaga R, Sueyoshi K Progression of carotid atherosclerosis in Japanese patients with coronary artery disease. Stroke. 23:1992;946-951.
10. Chambers BR, Norris JW Outcome in patients with asymptomatic neck bruits. New Engl J Med. 315:1986;860-865.
11. Salonen JT, Salonen R Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 11:1991;1245-1249.
12. Chimowitz MI, Weiss DG, Cohen SL, Starling MR, Hobson RW, Veterans Affairs Co-operative Study Group 167. Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Stroke 1994;25:759-65.
13. Kannel WB, Wolf PA, Verter J Manifestations of coronary disease redisposing to stroke. The Framingham Study. J Am Med Assoc. 25:1983;2942-2946.
14. Ostfeld AM A review of stroke epidemiology. Epidemiol Rev. 2:1980;136-152.
15. Turnipseed WD, Berkoff HA, Belzer FO Post-operative stroke in cardiac and peripheral vascular disease. Ann Surg. 192:1980;365-368.
16. Rodriguez G, Bertolini S, Nobili F, Arrigo A, Masturzo P, Elicio N, Gambaro M, Rosadini G Regional cerebral blood flow in familial hypercholesterolemia. Stroke. 25:1994;831-836.
17. Slack J Risks of ischaemic heart disease in familial hyperlipoproteinemic states. Lancet. 2:1969;1380-1382.
18. Wolf PA, Kannel WB, Verter J Current status of risk factors for stroke. Neurol Clin. 1:1983;317-343.
19. Heyman A, Karp HR, Heyden S, Bartel A, Cassel JC, Tyroler HA, Cornoni J, Hames CG, Stuart W Cerebrovascular disease in the bi-racial population of Evans County, Georgia. Stroke. 2:1971;509-518.
20. Salonen JT, Puska P, Tuomilehto J, Homan K Relation of blood pressure, serum lipids and smoking to the risk of cerebral stroke. Stroke. 13:1982;327-333.
21. Reed D, Yano K, Kagan A Lipids and lipoproteins as predictors of coronary heart disease, stroke and cancer in the Honolulu Heart Program. Am J Med. 80:1986;871-878.
22. Kagan A, Popper JS, Rhoads GG Factors related to stroke incidence in Hawaii Japanese men. Stroke. 11:1980;14-21.
23. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD Serum cholesterol levels and 6-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. New Engl J Med. 320:1989;904-910.
24. Takeya Y, Popper JS, Shimizu Y, Kato H, Rhoads GG, Kagan A Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of stroke in Japan and Hawaii. Stroke. 15:1984;15-24.
25. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
26. Smith GD Low blood cholesterol and non-atherosclerotic disease mortality: where do we stand? Eur Heart J. 18:1997;6-9.
27. Report of the Veterans Administration Co-operative Study of Atherosclerosis, Neurology Section. An evaluation of estrogenic substances in the treatment of cerebral vascular disease. Circulation 1966;SII:II-3-II-9.
28. Acheson J, Hutchinson EC Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis. 15:1972;177-183.
29. Veterans Administration Co-operative Study Group. The treatment of cerebrovascular disease with clofibrate. Stroke 1973;4:684-93.
30. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB Cholesterol reduction and the risk for stroke in men. Ann Intern Med. 119:1993;136-145.
31. Hebert PR, Gaziano JM, Hennekens CH An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 155:1995;50-55.
32. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis. 31:1978;5-14.
33. Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
34. The Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-64.
35. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med. 317:1987;1237-1245.
36. Dayton S, Pearce ML, Hashimoto S, Dixon WJ, Tomiyasu U A controlled clinical trial of a diet high in unsaturated fat. Circulation. 40SII:1969;II1-II63.
37. Frantz ID Jr, Dawson EA, Ashman PL, Gatewood LC, Bartsch GE, Kuba K et al. Test of effect of lipid-lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis. 9:1989;129-135.
38. Carlson LA, Rosenbamer G Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418.
39. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease, J Am Med Assoc 1975;231:360-81.
40. Report of a research committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet. 1968;2:693-700.
41. Leren P The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. Acta Med Scand Suppl. 466:1966;5-92.
42. Hjermann I, Velve Byre K, Holme I, Leren I Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomized trial in healthy men. Lancet. 2:1981;1303-1310.
43. Multiple Risk Factor interventional trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. J Am Med Assoc 1982;248:1465-77.
44. Miettinen TA, Huttunen JK, Naukkarinen V, Strandberg T, Mattila S, Kumlin T et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. J Am Med Assoc. 254:1985;2097-2102.
45. Buchwald H, Varco RL, Matts JP et al. Effect of partial ileal by-pass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. New Engl J Med. 323:1990;946-955.
46. Rossouw JE Non-CHD mortality in cholesterol-lowering trials. Cardiovasc Risk Factors. 5:1995;181-188.
47. Ulvenstam G, Bergstrand R, Johansson S, Vedin A, Wilhelmsson C, Wedel H, Aberg A, Wilhelmsen L Prognostic importance of cholesterol levels after myocardial infarction. Prev Med. 13:1984;355-366.
48. Brown BG, Zhao X-Q, Sacco DE, Albers JJ Lipid lowering and plaque regression, new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
49. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
50. Salonen R, Seppanen K, Rauramaa R, Salonen JT Prevalence of carotid atherosclerosis and serum cholesterol levels in Eastern Finland. Arteriosclerosis. 8:1988;788-792.
51. Crouse JR AWT and coronary heart disease. Touboul P-J, Crouse JR III Intima-Media Thickening and Atherosclerosis: Predicting the Risk. 1996;Parthenon Publishing, New York, London.
52. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu C, Liu C, Mack WJ, Alaupovic P Beneficial effects of colestipol-niacin therapy on the common carotid artery. Circulation. 88:1993;20-28.
53. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med. 124:1996;549-556.
54. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD Pravastatin, lipids and atherosclerosis in the carotid arteries PLAC-II. Am J Cardiol. 75:1995;455-459.
55. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 90:1994;1679-1687.
56. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park J-S, Salonen JT Kuopio Atherosclerosis Prevention Study KAPS. Circulation. 92:1995;1758-1764.
57. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alo G, Ventura A Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 101:1996;627-634.
58. Tegeler CH, Shi F, Morgan T Carotid stenosis in lacunar stroke. Stroke. 22:1991;1124-1128.
59. Giannoni MF, Spexiale F, Faraglia V, Sbarigia E, Zaccaria A, Lauri D, Fiorani P Minor asymptomatic carotid stenosis contralateral to carotid endarterectomy CEA: our experience. Eur J Vasc Surg. 5:1991;237-245.
60. Meissner I, Wiebers DO, Whisnant JP, O'Fallon M The natural history of asymptomatic carotid artery occlusive lesions. J Am Med Assoc. 258:1987;2704-2707.
61. Bock RW, Gray-Weale AC, Mock PA, Stats MA, Robinson DA, Irwig L, Lusby RJ The natural history of asymptomatic carotid artery disease. J Vasc Surg. 17:1993;160-171.
62. Golledge J, Cuming R, Ellis M, Beattie DK, Davies AH, Greenhalgh RM Clinical follow-up rather than duplex surveillance after carotid endarterectomy. J Vasc Surg. 25:1997;55-63.
63. Naylor AR, Howlett J, Gillespie I, Allan P, Ruckley CV Fate of the non-operated carotid artery after contralateral endarterectomy. Br J Surg. 82:1995;44-48.
64. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engl J Med 1991;325:445-53.
65. Manolio TA, Kronmal RA, Burke GL, O'Leary DH, Price TR For the CHS Collaborative Research Group. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. Stroke. 27:1996;1479-1486.
66. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 25:1989;382-390.
67. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe 70-99% or with mild 0-29% carotid stenosis. Lancet 1991;337:1235-43.
68. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, Colling C, Eskridge J, Deykin D, Winn R Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. J Am Med Assoc. 266:1991;3289-3294.
69. Hobson RW, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, Wright CB Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. New Engl J Med. 328:1993;221-227.
70. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for Asymptomatic Carotid Artery Stenosis. J Am Med Assoc 1995;273:1421-28.
71. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 4S. Lancet 1994;344:1383-89.
72. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini J Reduction in cardiovascular events during pravastatin therapy. Circulation. 92:1995;2419-2425.
73. Crouse JR III, Byington RP, Furberg CD Reductase inhibitor monotherapy prevents stroke. Circulation. 94:1996;540.
74. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled double-blind trials with HMG-CoA reductase inhibitors. Stroke. 28:1997;946-950.
75. Crouse JR III, Byington RP, Hoen HM, Furberg CD Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 157:1997;1305-1310.
76. Hebert PR, Gaziano JM, Chan KS, Hennekens CH Cholesterol lowering with statin drugs, risk of stroke and total mortality. J Am Med Assoc. 278:1997;313-321.
77. Mercuri M, Bond MG, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, Descovich G, Ricci G, Rubba P, Mancini M, Gallus G, Bianchi G, D'Alo G, Ventura A Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 101:1996;627-634.
78. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/l 200-300 mg/dl plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-37.
79. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN, Nash DT, Langendorfer A Expanded clinical evaluation of lovastatin EXCEL study results. Circulation. 85:1992;1293-1303.
80. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME Pravastatin limitation of atherosclerosis in the coronary arteries PLAC I: reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 26:1995;1133-1139.
81. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD Pravastatin, lipids and atherosclerosis in the carotid arteries PLAC-II. Am J Cardiol. 75:1995;455-459.
82. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 91:1995;2528-2540.
83. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 335:1996;1001-1009.
84. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, MARS Research Group. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study MARS. Ann Intern Med 1993;119:969-76.
85. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
86. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study MAAS. Lancet 1994;344:633-38.
87. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, O'Neill WW, Frazier JE, Cohen-Bernstein CL, Robbins DC, Brown CL, Alexander RW, Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty, New Engl J Med 1994;331:1331-37.
88. Behar S, Tanne D, Abinader E, Agmon J, Barzilai J, Friedman Y, Kaplinsky E, Kauli N, Kishon Y, Palant A, Peled B, Reisin L, Schlesinger Z, Zahavi I, Zion M, Goldbourt U Cerebrovascular accident complicating acute myocardial infarction: incidence, clinical significance and short- and long-term mortality rates. Am J Med. 91:1991;45-50.
89. Visser CA, Kan G, Meltzer RS, Dunning AJ, Roelandt J Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional exhocardiographic study of 119 patients. JACC. 5:1985;1276-1280.
90. Levorstad K, Vatne K, Brodahl U, Aakhus T, Simonsen S, Vik H Cerebral thromboembolic complications associated with the use of a nonionic contrast medium in coronary angiography. Acta Radiol. 36:1995;69-71.
91. Libman RB, Wirkowski E, Neystat M, Barr W, Gelb S, Graver M Stroke associated with cardiac surgery. Arch Neurol. 54:1997;83-87.
92. Dibert SW, Asconape J Embolic pontine infarction in a nonhypertensive patient following coronary angioplasty. J Neuroimaging. 5:1995;194-195.
93. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN for the V-HeFT VA co-operative studies group. Incidence of thromboembolic events in congestive heart failure. Circulation 1983;87:94-101.
94. Baker DW, Wright RF Management of heart failure IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. J Am Med Assoc. 272:1994;1614-1618.
95. Murros KE, Evans GW, Toole JF, Howard G, Rose LA Cerebral infarction in patients with transient ischemic attacks. J Neurol. 236:1989;182-184.
96. Howard G, Evans GW, Crouse JR III, Toole JF, Ryu JE, Tegeler C, Frye-Pierson J, Mitchell E, Sanders L A prospective reevaluation of transient ischemic attacks as a risk factor for death and fatal or nonfatal cardiovascular events. Stroke. 25:1994;342-345.
97. American Heart Association Heart and Stroke Facts: 1996 Statistical Supplement. American Heart Association, Dallas, TX, 1996.
98. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335:1990;765-774.
99. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
100. Crouse JR III Assessment and management of carotid disease. Annu Rev Med. 43:1992;301-316.